Copyright 2009 Medical News Today Latest ADHD News From Medical News Today. http://www.medicalnewstoday.com/sections/adhd/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 14 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170933.php http://www.medicalnewstoday.com/articles/170933.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. ADHD Fri, 13 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/170919.php http://www.medicalnewstoday.com/articles/170919.php Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University. Mental Health Fri, 13 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170813.php http://www.medicalnewstoday.com/articles/170813.php Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. ADHD Wed, 11 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170475.php http://www.medicalnewstoday.com/articles/170475.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. ADHD Tue, 10 Nov 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/170456.php http://www.medicalnewstoday.com/articles/170456.php Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD. "It is important that pupils are offered the support to which they are entitled", says Jakob Asberg in a new thesis at the University of Gothenburg. "Pupils with these neuropsychiatric disorders are often reported as having problems with spoken and written activities. Autism Tue, 03 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169555.php http://www.medicalnewstoday.com/articles/169555.php BioBehavioral Diagnostics Company announced that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D. ADHD Sat, 31 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169378.php http://www.medicalnewstoday.com/articles/169378.php Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented. ADHD Fri, 30 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169339.php http://www.medicalnewstoday.com/articles/169339.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu. ADHD Thu, 29 Oct 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/169169.php http://www.medicalnewstoday.com/articles/169169.php It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr. Pregnancy / Obstetrics Thu, 29 Oct 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169145.php http://www.medicalnewstoday.com/articles/169145.php Schoolchildren with attention deficit/hyperactivity disorder are substantially more likely to engage in many types of criminal activity such as burglary, theft and drug dealing as they grow older, a new study by the Yale School of Public Health has found. The research was published in The Journal of Mental Health Policy and Economics. ADHD Thu, 29 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169097.php http://www.medicalnewstoday.com/articles/169097.php It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr. ADHD Thu, 29 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/169043.php http://www.medicalnewstoday.com/articles/169043.php Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week. Heart Disease Sun, 25 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168544.php http://www.medicalnewstoday.com/articles/168544.php KemPharm, Inc. announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. ADHD Sat, 24 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168497.php http://www.medicalnewstoday.com/articles/168497.php Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. ADHD Sat, 24 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/168509.php http://www.medicalnewstoday.com/articles/168509.php Parents have long lectured their children about the mind-numbing effects of playing video games all day. And a new Iowa State University study has found that high volume action video game players -- those who play around 40 hours per week -- actually had more difficulty keeping focused on tasks requiring longer, more proactive attention than those who played video games less than a couple of hours a week. IT / Internet / E-mail Fri, 23 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/168416.php http://www.medicalnewstoday.com/articles/168416.php Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. ADHD Thu, 22 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/168318.php http://www.medicalnewstoday.com/articles/168318.php Rats exposed to high doses of amphetamines at an age that corresponds to the later years of human adolescence display significant memory deficits as adults - long after the exposure ends, researchers report. The declines in short-term or "working" memory are most pronounced when the rats are exposed during adolescence, rather than as adults, the researchers found. Alcohol / Addiction / Illegal Drugs Wed, 14 Oct 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/167265.php http://www.medicalnewstoday.com/articles/167265.php Video game players are often accused of passively reacting to tasks that are spoon fed to them through graphics and stimuli on the screen. A group of researchers from Iowa State University shows that playing lots of video games has different effects on two types of cognitive activity, proactive and reactive attention. Proactive attention can be thought of as a sort of "gearing up" mechanism. IT / Internet / E-mail Thu, 08 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/166570.php http://www.medicalnewstoday.com/articles/166570.php Expectant mothers who eat excessive quantities of liquorice during pregnancy could adversely affect their child's intelligence and behaviour, a study has shown. A study of eight year old children whose mothers ate large amounts of liquorice when pregnant found they did not perform as well as other youngsters in cognitive tests. They were also more likely to have poor attention spans and show disruptive behaviour such as ADHD (attention deficit hyperactivity disorder). Pregnancy / Obstetrics Sun, 04 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/166094.php http://www.medicalnewstoday.com/articles/166094.php Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD). The submission is based on the successful completion of Phase III clinical trials demonstrating statistical significance when Clonicel was used to treat ADHD in children and adolescents. ADHD Fri, 25 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/165130.php http://www.medicalnewstoday.com/articles/165130.php When they think of attention deficit hyperactivity disorder, most people think of squirming kids unable to sit still. ADHD, as it is more generally known, is one of the most common disorders of childhood. But symptoms of ADHD often linger into adulthood. Approximately 2 to 4 percent of college students report significant symptoms of ADHD such as difficulty with attention, impulse control, and restlessness. ADHD Fri, 25 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/165141.php http://www.medicalnewstoday.com/articles/165141.php In an effort to help one of the most under studied groups of sufferers of attention deficit hyperactivity disorder (ADHD), researchers at University of Rhode Island and Lehigh University have kicked off the first-ever controlled pharmacological study for treatment of ADHD amongst college students. ADHD Wed, 16 Sep 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/164150.php http://www.medicalnewstoday.com/articles/164150.php Attention deficit/hyperactivity disorder, ADHD, is one of the most common neuropsychiatric disorders of childhood. Worldwide, 3% of children are affected with the disorder. Key symptoms of ADHD include age-inappropriate hyperactive and impulsive behaviour and/or a reduced ability to focus attention. ADHD Wed, 16 Sep 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/164114.php http://www.medicalnewstoday.com/articles/164114.php A panel of physicians and scientists will report on the benefits of a simple meditation practice for aiding students diagnosed with ADHD during a national medical webinar, which will be hosted by the David Lynch Foundation on Wednesday, September 30, 12 noon (ET). http://www.adhd-tm. ADHD Tue, 15 Sep 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/163864.php http://www.medicalnewstoday.com/articles/163864.php Results from brain scans suggest an association between a reduction in the transmission of dopamine markers with symptoms of inattention for individuals with attention deficit/hyperactivity disorder (ADHD), according to a preliminary study in the September 9 issue of JAMA. ADHD is a childhood psychiatric disorder that frequently persists into adulthood, and is estimated to affect 3 percent to 5 percent of the U.S. ADHD